HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s stock price traded down 6.4% on Tuesday . The stock traded as low as $3.20 and last traded at $3.22. 200 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 925 shares. The stock had previously closed at $3.44.
HLS Therapeutics Stock Performance
The business’s 50-day moving average is $3.07 and its two-hundred day moving average is $2.79.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
See Also
- Five stocks we like better than HLS Therapeutics
- What is Put Option Volume?
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Canadian Penny Stocks: Can They Make You Rich?
- The Top-Ranked Insider Buys From April by Market Cap
- ETF Screener: Uses and Step-by-Step Guide
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
